Keywords: Dainippon Sumitomo, Intercept Pharma, Obeticholic, Hepatology, Liver disease

Dainippon Sumitomo in up to $315 million deal with Intercept for liver disease drug obeticholic

Article | 31 March 2011

Print This

Japanese drug major Dainippon Sumitomo Pharma (4506:JP) has entered into an exclusive licensing agreement with privately held US firm ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in